These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy. Sibaud V Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113 [TBL] [Abstract][Full Text] [Related]
25. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. Weber JS; Postow M; Lao CD; Schadendorf D Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894 [TBL] [Abstract][Full Text] [Related]
26. Strategies for improving the management of immune-related adverse events. Naing A; Hajjar J; Gulley JL; Atkins MB; Ciliberto G; Meric-Bernstam F; Hwu P J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33310772 [TBL] [Abstract][Full Text] [Related]
27. Management of Steroid-Refractory Gastrointestinal Immune-Related Adverse Events. Brongiel S; Rychalsky KL; Luon D; Johnson AR; Price C; Abdelghany O Ann Pharmacother; 2023 Feb; 57(2):148-155. PubMed ID: 35656843 [TBL] [Abstract][Full Text] [Related]
28. When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. Ziogas DC; Gkoufa A; Cholongitas E; Diamantopoulos P; Anastasopoulou A; Ascierto PA; Gogas H J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33144335 [TBL] [Abstract][Full Text] [Related]
29. Biomarkers for immune-related toxicities of checkpoint inhibitors: current progress and the road ahead. Patil PD; Burotto M; Velcheti V Expert Rev Mol Diagn; 2018 Mar; 18(3):297-305. PubMed ID: 29430978 [TBL] [Abstract][Full Text] [Related]
30. Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung Cancer. Owen DH; Wei L; Bertino EM; Edd T; Villalona-Calero MA; He K; Shields PG; Carbone DP; Otterson GA Clin Lung Cancer; 2018 Nov; 19(6):e893-e900. PubMed ID: 30197259 [TBL] [Abstract][Full Text] [Related]
31. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians. Hryniewicki AT; Wang C; Shatsky RA; Coyne CJ J Emerg Med; 2018 Oct; 55(4):489-502. PubMed ID: 30120013 [TBL] [Abstract][Full Text] [Related]
32. [Current research status on immune-related adverse events]. Hua YW; Zhao L Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):271-276. PubMed ID: 35340178 [TBL] [Abstract][Full Text] [Related]
33. Optimizing Care for Patients With Adverse Events From Immunotherapeutics. Sheehan K; Price C; Hafez N Cancer J; 2020; 26(6):537-542. PubMed ID: 33298725 [TBL] [Abstract][Full Text] [Related]
34. [Side effects of cancer immunotherapies : important role for the clinical immunologist]. Obeid M Rev Med Suisse; 2019 Jan; 15(N° 632-633):17-19. PubMed ID: 30629360 [TBL] [Abstract][Full Text] [Related]
35. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update. Nagai H; Muto M Int J Clin Oncol; 2018 Jun; 23(3):410-420. PubMed ID: 29516216 [TBL] [Abstract][Full Text] [Related]
36. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Delanoy N; Michot JM; Comont T; Kramkimel N; Lazarovici J; Dupont R; Champiat S; Chahine C; Robert C; Herbaux C; Besse B; Guillemin A; Mateus C; Pautier P; Saïag P; Madonna E; Maerevoet M; Bout JC; Leduc C; Biscay P; Quere G; Nardin C; Ebbo M; Albigès L; Marret G; Levrat V; Dujon C; Vargaftig J; Laghouati S; Croisille L; Voisin AL; Godeau B; Massard C; Ribrag V; Marabelle A; Michel M; Lambotte O Lancet Haematol; 2019 Jan; 6(1):e48-e57. PubMed ID: 30528137 [TBL] [Abstract][Full Text] [Related]
37. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948 [TBL] [Abstract][Full Text] [Related]
38. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer. Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524 [TBL] [Abstract][Full Text] [Related]
39. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift? Madden DL Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148 [TBL] [Abstract][Full Text] [Related]